Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 plus Opdivo in advanced metastatic gastric cancer
CTR20222492Phase 2Active
- Sponsor
- Sinopharm CNBG-Virogin Biotech
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VG161 and nivolumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Sinopharm CNBG-Virogin Biotech. Primary endpoints: RP2D/MTD of VG161 in combination with nivolumab, Dose-limiting toxicities and 3 more. Started Mar 2023; status: active.
02
Drugs
VG161nivolumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20222492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222492.